MX2021004185A - Polipeptidos analogos de la amilina humana y sus metodos de uso. - Google Patents

Polipeptidos analogos de la amilina humana y sus metodos de uso.

Info

Publication number
MX2021004185A
MX2021004185A MX2021004185A MX2021004185A MX2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A MX 2021004185 A MX2021004185 A MX 2021004185A
Authority
MX
Mexico
Prior art keywords
methods
analog polypeptides
amylin
amylin analog
polypeptides
Prior art date
Application number
MX2021004185A
Other languages
English (en)
Inventor
Ved P Srivastava
William Blackwell
James M Way
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of MX2021004185A publication Critical patent/MX2021004185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Polipéptidos aislados que son análogos de la amilina humana; los polipéptidos análogos de amilina divulgados tienen propiedades fisicoquímicas beneficiosas relacionadas con la amilina endógena, tales como una vida media (ti/2) de eliminación más prolongada y una solubilidad y estabilidad térmica mejoradas; esta invención también se relaciona con métodos para usar los polipéptidos análogos de amilina divulgados en una variedad de indicaciones terapéuticas, así como métodos para producir los mismos; los polipéptidos análogos de amilina divulgados son de particular utilidad en los métodos de tratamiento de enfermedades o trastornos metabólicos, tal como las diabetes de los tipos 1 y 2 y también proveen pérdida de peso.
MX2021004185A 2018-10-11 2019-10-10 Polipeptidos analogos de la amilina humana y sus metodos de uso. MX2021004185A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11
PCT/US2019/055696 WO2020077129A1 (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Publications (1)

Publication Number Publication Date
MX2021004185A true MX2021004185A (es) 2021-09-08

Family

ID=68393080

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004185A MX2021004185A (es) 2018-10-11 2019-10-10 Polipeptidos analogos de la amilina humana y sus metodos de uso.

Country Status (14)

Country Link
US (1) US20200115430A1 (es)
EP (1) EP3864031A1 (es)
JP (1) JP2022504596A (es)
KR (1) KR20210091705A (es)
CN (1) CN113195524A (es)
AR (1) AR116632A1 (es)
AU (1) AU2019357621A1 (es)
BR (1) BR112021006823A2 (es)
CA (1) CA3116023A1 (es)
IL (1) IL282079A (es)
MX (1) MX2021004185A (es)
SG (1) SG11202103586UA (es)
TW (1) TW202028228A (es)
WO (1) WO2020077129A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021260870A1 (en) * 2020-04-20 2022-12-08 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
KR20230073176A (ko) * 2020-09-24 2023-05-25 구브라 에이피에스 개선된 아밀린 수용체(hAMY3R) 효능을 갖는 HAM15-52 유사체
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
SI9420051A (en) 1993-08-09 1996-12-31 Biomeasure Inc Chemical modified peptide derivatives, process for their preparation and their use in human therapy
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
WO1997027840A1 (en) 1996-02-02 1997-08-07 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
DE69822208T2 (de) 1997-12-29 2005-04-28 Alza Corp., Mountain View Osmotisches verabreichungssystem mit stöpselrückhaltemechanismus
ES2378675T3 (es) 1997-12-30 2012-04-16 Intarcia Therapeutics, Inc Sistema de suministro de un agente beneficioso con una membrana obturadora
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
NZ527241A (en) 1998-12-07 2004-12-24 Sod Conseils Rech Applic Analogues of GLP-1
NZ512671A (en) 1998-12-31 2003-12-19 Alza Corp Osmotic delivery system having space efficient piston
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1328256B1 (en) 1999-12-21 2005-10-19 Alza Corporation Valve for osmotic devices
CN1462191B (zh) 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
EA008837B1 (ru) 2000-06-16 2007-08-31 Эли Лилли Энд Компани Аналоги глюкагоноподобного пептида и их применение
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
WO2002098348A2 (en) 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
IL160493A0 (en) 2001-08-23 2004-07-25 Lilly Co Eli Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1551493B1 (en) 2002-06-26 2007-10-31 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
JP2006521897A (ja) 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5703226B2 (ja) * 2008-10-21 2015-04-15 ノヴォ ノルディスク アー／エス アミリン誘導体
WO2012162547A2 (en) * 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates

Also Published As

Publication number Publication date
CA3116023A1 (en) 2020-04-16
US20200115430A1 (en) 2020-04-16
TW202028228A (zh) 2020-08-01
WO2020077129A1 (en) 2020-04-16
KR20210091705A (ko) 2021-07-22
JP2022504596A (ja) 2022-01-13
SG11202103586UA (en) 2021-05-28
IL282079A (en) 2021-05-31
AR116632A1 (es) 2021-05-26
CN113195524A (zh) 2021-07-30
AU2019357621A1 (en) 2021-05-27
BR112021006823A2 (pt) 2021-07-27
EP3864031A1 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
MX2021004185A (es) Polipeptidos analogos de la amilina humana y sus metodos de uso.
AU2024202155A1 (en) Glucagon-Receptor Selective Polypeptides And Methods Of Use Thereof
MX2022005399A (es) Compuestos.
PH12020551742A1 (en) Gip derivatives and uses thereof
MA49339A (fr) Conjugués insuline-fc à extension oligomère
NZ593813A (en) Glucagon analogues
WO2019070891A8 (en) Gene therapies for lysosomal disorders
MY193457A (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
MX2019002599A (es) Analogos de amilina.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
PH12020551659A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
WO2019212356A8 (en) Tetrazines for high click conjugation yield in vivo and high click release yield
MX2022007351A (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos.
ZA202201828B (en) Therapeutic fusion proteins
PH12019502850A1 (en) AMIDE DERIVATIVES AS Nav1.7 AND Nav1.8 BLOCKERS
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2022003820A (es) Metodos de tratamiento para modificar la hermodinamica.
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.
AU2017248103A1 (en) Tobacco leaf extract and use thereof for the treatment of tobacco addiction
PH12021550424A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants